Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;86(Pt 3):445-456.
doi: 10.1016/j.semcancer.2022.02.004. Epub 2022 Feb 4.

The altered lipidome of hepatocellular carcinoma

Shawn Lu Wen Tan  1 , Erez Israeli  2 , Russell E Ericksen  3 , Pierce K H Chow  4 , Weiping Han  5
Affiliations
Review

The altered lipidome of hepatocellular carcinoma

Shawn Lu Wen Tan et al. Semin Cancer Biol. 2022 Nov.

Abstract

Alterations in metabolic pathways are a hallmark of cancer. A deeper understanding of the contribution of different metabolites to carcinogenesis is thus vitally important to elucidate mechanisms of tumor initiation and progression to inform therapeutic strategies. Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide and its altered metabolic landscape is beginning to unfold with the advancement of technologies. In particular, characterization of the lipidome of human HCCs has accelerated, and together with biochemical analyses, are revealing recurrent patterns of alterations in glycerophospholipid, sphingolipid, cholesterol and bile acid metabolism. These widespread alterations encompass a myriad of lipid species with numerous roles affecting multiple hallmarks of cancer, including aberrant growth signaling, metastasis, evasion of cell death and immunosuppression. In this review, we summarize the current trends and findings of the altered lipidomic landscape of HCC and discuss their potential biological significance for hepatocarcinogenesis.

Keywords: Cancer; Hepatocellular carcinoma; Lipid; Lipidomics; Metabolism.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest P.K.H.C. has served on the Scientific Advisory Boards of Ipsen, BMS, Bayer, New B Innovation, MSD Pharma, BTG Plc, Guerbet, Roche, L.E.K. Consulting, AstraZeneca, Eisai, Genentech, IQVIA, Abbott. He serves as the Chair of the Scientific Advisory Boards of SIRTex Medical, Oncosil and AUM Bioscience. He is also the Chair of the IMbrave050 steering committee and serves as the founding board member of AVATAMED. The other authors declare no conflicts of interest.

Publication types

LinkOut - more resources